The launch of a new product, especially a generic version of a well-known drug like Levaquin, typically generates positive revenue prospects. Given the specific market size of $7.1 million annually for Levofloxacin Oral Solution, this launch could significantly impact ANIP's financials and stock performance in the short term. The confidence in this analysis is high due to the clear market size estimation and the product's relevance to ANIP's portfolio.